Butler LM - Search Results

1

Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.

Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource. Bianco-Miotto T, et al. Among authors: butler lm. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20841388

2

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Butler LM, et al. Cancer Res. 2000 Sep 15;60(18):5165-70. Cancer Res. 2000. PMID: 11016644

3

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. Butler LM, et al. Clin Cancer Res. 2001 Apr;7(4):962-70. Clin Cancer Res. 2001. PMID: 11309347

4

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. Butler LM, et al. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5. doi: 10.1073/pnas.182372299. Epub 2002 Aug 20. Proc Natl Acad Sci U S A. 2002. PMID: 12189205 Free PMC article.

5

Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.

Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Scher HI, et al. Among authors: butler lm. Endocr Relat Cancer. 2004 Sep;11(3):459-76. doi: 10.1677/erc.1.00525. Endocr Relat Cancer. 2004. PMID: 15369448 Review.

6

GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.

Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD, Coetzee GA. Shen HC, et al. Among authors: butler lm. Biol Chem. 2005 Jan;386(1):69-74. doi: 10.1515/BC.2005.009. Biol Chem. 2005. PMID: 15843149

7

Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.

Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD. Buchanan G, et al. Among authors: butler lm. Cancer Res. 2005 Sep 15;65(18):8487-96. doi: 10.1158/0008-5472.CAN-04-3077. Cancer Res. 2005. PMID: 16166329 Free article.

8

Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.

Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M, Brown MP, Tilley WD. Butler LM, et al. Mol Endocrinol. 2006 May;20(5):1009-24. doi: 10.1210/me.2004-0401. Epub 2006 Jan 19. Mol Endocrinol. 2006. PMID: 16423882

9

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. Butler LM, et al. Int J Cancer. 2006 Aug 15;119(4):944-54. doi: 10.1002/ijc.21939. Int J Cancer. 2006. PMID: 16550602

10

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM. Marrocco DL, et al. Among authors: butler lm. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11. Mol Cancer Ther. 2007. PMID: 17218635

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

352 results

Search Page

Filters